Compare Enovix Corporation (ENVX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Repligen Corporation Common Stock — how do they compare? Enovix Corporation trades at $2.41 (market cap $550.82M), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 20.2× Enovix Corporation's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Repligen Corporation Common Stock for 0 Days on average.
| ENVX | RGEN | |
|---|---|---|
Market Cap | $550.82M | $11.14B |
Volume | 5,977,872 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $13.19 | $194.57 |
52-Week Low | $2.44 | $102.87 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $612.51M | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.51, down 3.09% on the day, reflecting bearish technical signals and negative profitability. The company reported a net loss of -$156.74M in 2025, with revenue of $31.82M, while recent quarterly EPS has consistently beaten expectations. Key developments include a CEO transition in August 2026 and expansion of drone battery capacity in South Korea.
Despite deep losses and cash burn, analyst consensus remains bullish with a $9.60 price target, citing potential in defense and smartphone battery markets. Risks include high cash burn, leadership changes, and competitive pressures. The stock's outlook hinges on successful commercialization and margin improvement.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
